Q-omics provides the consensus-scored ZNF773 profile across patient tissues and cancer cell-line models. ZNF773 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZNF773 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ZNF773 RNA expression shows 20,843 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, THCA, and ACC as cancer lineages where ZNF773 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF773 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF773 survival associations across molecular data types. ZNF773 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF773 RNA expression–survival associations across cancer types. High ZNF773 expression shows unfavorable associations in LGG and LUSC, but favorable associations in SCLC, KIRC, PAAD and UVM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for ZNF773 RNA expression.
This table summarizes ZNF773 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF773. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF773 shows lower tumor expression in THCA and COAD and higher tumor expression in LIHC, HNSC, CHOL and BLCA. The THCA box plot shows higher ZNF773 RNA expression in normal versus tumor tissue (log2 FC = −0.537, t-test p < 0.001).
This table shows molecular features associated with ZNF773 in patient tissues and cancer cell lines. In patient samples, ZNF773 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF773 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
